港股異動 | RITAMIX(1936.HK)首日上市高開101%
格隆匯5月13日丨RITAMIX(1936.HK)今日上市高開101%,報2.01港元,暫成交3030萬港元,最新總市值10億港元。公司是一間紮根於馬來西亞的公司,主要從事分銷動物飼料添加劑及較少的人類食品配料;及生產動物飼料添加劑預混料。2017年至2019年收益分別為1.08億、1.28億、1.26億令吉。公司此次發售1.25億股,每股定價1港元,每手2000股。公開發售股份1250萬股,佔發售股份總數的10%,公開發售階段獲5.33倍認購。此外,國際發售獲輕微超額認購,發售股份最終數目為1.125億股,相當於發售股份總數的90%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.